Azitra, Inc. AZTR · Stock Open Azitra, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Azitra, Inc. Analysis (AZTR)
Is Azitra, Inc. a good investment? Azitra, Inc. (AZTR) is currently trading at 0.0720 USD. Market analysts have a consensus price target of 0.67 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 8.39. This relatively low multiple may signal that Azitra, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Azitra, Inc. is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -0.52.
Investor FAQ
Does Azitra, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Azitra, Inc.?
Azitra, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -0.28.
Company Profile
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.
| Split Date | Split Ratio to 1 |
|---|---|
| July 1, 2024 | 0.03 |
| Aug. 21, 2025 | 6.66 |
Community Discussion